Wedbush increased their Q2 2025 earnings per share estimates for SpringWorks Therapeutics in a research report issued on Wednesday, February 12th. Wedbush analyst D. Nierengarten now expects that the ...
Stock analysts at HC Wainwright dropped their FY2024 earnings per share estimates for SpringWorks Therapeutics in a research note issued on Wednesday, February 12th. HC Wainwright analyst R. Burns now ...
Discover the latest strategic moves of Duquesne Family Office's $3.72B portfolio, including new stakes, increased investments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback